Page last updated: 2024-08-25

zoledronic acid and everolimus

zoledronic acid has been researched along with everolimus in 13 studies

Research

Studies (13)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (15.38)	29.6817
2010's	10 (76.92)	24.3611
2020's	1 (7.69)	2.80

Authors

Authors	Studies
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Corey, E; Gross, TS; Morgan, TM; Pitts, TE; Poliachik, SL; Vessella, RL	1
Fricker, J	1
Battaglia, S; Blanchard, F; Brion, R; Charrier, C; Denis, MG; Heymann, D; Mitrofan, L; Mönkkönen, J; Moriceau, G; Ory, B; Pilet, P; Rédini, F; Riganti, C; Shultz, LD	1
Abbruzzese, A; Borghi, MO; Caraglia, M; Castiglioni, S; Colao, A; Crinò, L; Dicitore, A; Faggiano, A; Ferolla, P; Ferone, D; Hofland, L; Ramundo, V; Severino, R; Sperlongano, P; Vitale, G	1
Agerbaek, M; Donskov, F; Fode, K; Folkmar, TB; Smidt-Hansen, T	1
Afonso, PD; Febbo, PG; Foye, A; George, DJ; Madden, JF; Morris, KK; Roy Choudhury, K; Spritzer, CE; Turnbull, JD; Vinson, EN	1
Jung, HD; Jung, YS; Kim, DW; Park, HS	1
Lu, S; Song, Z; Yang, S; Yang, X; Yu, Y; Zhang, J	1
Broom, RJ; Deva, S; Duffey, S; Findlay, MP; Fong, PC; Forgeson, G; Grey, A; Hanning, FJ; Harris, DL; Hinder, V; Jameson, MB; North, RT; O'Donnell, A; Pollard, S; Proctor, J; Sharples, K	1
Amadori, D; Bongiovanni, A; De Vita, A; Ibrahim, T; Liverani, C; Mercatali, L; Miserocchi, G; Recine, F; Spadazzi, C	1
Auernhammer, CJ; Bechmann, N; Beuschlein, F; Bihl, M; Bornstein, SR; Broglie Däppen, M; Eisenhofer, G; Fankhauser, M; Fassnacht, M; Friemel, J; Grossman, AB; Gulde, S; Hantel, C; Helm, J; Klink, B; Knösel, T; Kroiss, M; Ladurner, R; Lauseker, M; Lottspeich, C; Maurer, J; Nölting, S; Pacak, K; Pellegata, NS; Pietzsch, J; Reincke, M; Reul, A; Richter, S; Schober, L; Schütze, I; Spoettl, G; Ullrich, M; Vetter, D; Wang, K; Weber, A; Wenter, VUJ; William, D; Ziegler, CG	1

Reviews

1 review(s) available for zoledronic acid and everolimus

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Trials

2 trial(s) available for zoledronic acid and everolimus

Article	Year
Bone marrow biopsy: RNA isolation with expression profiling in men with metastatic castration-resistant prostate cancer--factors affecting diagnostic success. Radiology, 2013, Volume: 269, Issue:3 Topics: Biopsy; Bone Density Conservation Agents; Bone Marrow; Diphosphonates; Everolimus; Gene Expression Profiling; Humans; Imidazoles; Immunosuppressive Agents; Male; Prostatic Neoplasms; RNA; Sirolimus; Tomography, X-Ray Computed; Ultrasonography, Interventional; Zoledronic Acid	2013
Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: a randomized first-line phase II trial. Clinical genitourinary cancer, 2015, Volume: 13, Issue:1 Topics: Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Collagen Type I; Diphosphonates; Everolimus; Female; Humans; Imidazoles; Kidney Neoplasms; Male; Middle Aged; Peptides; Prospective Studies; Sirolimus; Treatment Outcome; Zoledronic Acid	2015

Article

Year

Bone marrow biopsy: RNA isolation with expression profiling in men with metastatic castration-resistant prostate cancer--factors affecting diagnostic success.

Radiology, 2013, Volume: 269, Issue:3

Topics: Biopsy; Bone Density Conservation Agents; Bone Marrow; Diphosphonates; Everolimus; Gene Expression Profiling; Humans; Imidazoles; Immunosuppressive Agents; Male; Prostatic Neoplasms; RNA; Sirolimus; Tomography, X-Ray Computed; Ultrasonography, Interventional; Zoledronic Acid

2013

Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: a randomized first-line phase II trial.

Clinical genitourinary cancer, 2015, Volume: 13, Issue:1

Topics: Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Collagen Type I; Diphosphonates; Everolimus; Female; Humans; Imidazoles; Kidney Neoplasms; Male; Middle Aged; Peptides; Prospective Studies; Sirolimus; Treatment Outcome; Zoledronic Acid

2015

Other Studies

10 other study(ies) available for zoledronic acid and everolimus

Article	Year
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid. The Prostate, 2008, Jun-01, Volume: 68, Issue:8 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Docetaxel; Everolimus; Humans; Imidazoles; Male; Mice; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Sirolimus; Taxoids; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Zoledronic Acid	2008
San Antonio Breast Cancer Symposium. The Lancet. Oncology, 2009, Volume: 10, Issue:1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Diphosphonates; Everolimus; Female; Humans; Imidazoles; Lapatinib; Letrozole; Nitriles; Quinazolines; Sirolimus; Tamoxifen; Trastuzumab; Triazoles; Zoledronic Acid	2009
Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process. Cancer research, 2010, Dec-15, Volume: 70, Issue:24 Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Cell Growth Processes; Cell Line, Tumor; Diphosphonates; Drug Resistance, Neoplasm; Drug Synergism; Everolimus; Humans; Imidazoles; Male; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Osteosarcoma; Protein Prenylation; ras Proteins; Rats; Sirolimus; TOR Serine-Threonine Kinases; Zoledronic Acid	2010
Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study. Journal of cellular and molecular medicine, 2012, Volume: 16, Issue:7 Topics: Aged; Apoptosis; beta-Galactosidase; Blotting, Western; Calcitonin; Cell Cycle; Cell Proliferation; Cellular Senescence; Diphosphonates; Everolimus; Humans; Imidazoles; Male; Middle Aged; Sirolimus; Thyroid Neoplasms; Thyroidectomy; Treatment Outcome; Zoledronic Acid	2012
Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2013, Volume: 71, Issue:9 Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Cohort Studies; Diphosphonates; Everolimus; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Imidazoles; Indazoles; Indoles; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Radiography, Panoramic; Retrospective Studies; Sirolimus; Sorafenib; Spinal Cord Compression; Sulfonamides; Sunitinib; Survival Rate; Zoledronic Acid	2013
Osteonecrosis of the jaw related to everolimus: a case report. The British journal of oral & maxillofacial surgery, 2013, Volume: 51, Issue:8 Topics: Angiogenesis Inhibitors; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Everolimus; Follow-Up Studies; Humans; Imidazoles; Male; Mandibular Diseases; Middle Aged; Osteonecrosis; Sirolimus; Thyroid Neoplasms; Thyroidectomy; Zoledronic Acid	2013
Everolimus and zoledronic acid--a potential synergistic treatment for lung adenocarcinoma bone metastasis. Acta biochimica et biophysica Sinica, 2014, Volume: 46, Issue:9 Topics: Animals; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Diphosphonates; Drug Synergism; Drug Therapy, Combination; Everolimus; Humans; Imidazoles; Lung Neoplasms; Mice; Neoplasm Invasiveness; Phosphorylation; Ribosomal Protein S6 Kinases, 70-kDa; Sirolimus; Zoledronic Acid	2014
The Effect of Everolimus in an In Vitro Model of Triple Negative Breast Cancer and Osteoclasts. International journal of molecular sciences, 2016, Nov-01, Volume: 17, Issue:11 Topics: Antineoplastic Agents; Biomarkers; Blotting, Western; Bone Neoplasms; Cell Differentiation; Cell Line, Tumor; Cells, Cultured; Coculture Techniques; Denosumab; Diphosphonates; Everolimus; Gene Expression; Humans; Imidazoles; Intercellular Adhesion Molecule-1; Interleukin-6; MCF-7 Cells; Models, Biological; Osteoclasts; Osteonectin; RANK Ligand; Receptors, CXCR4; Reverse Transcriptase Polymerase Chain Reaction; Transforming Growth Factor beta; Triple Negative Breast Neoplasms; Zoledronic Acid	2016
Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures. Endocrine-related cancer, 2022, 05-09, Volume: 29, Issue:6 Topics: Adrenal Gland Neoplasms; Animals; Antineoplastic Agents; Everolimus; Humans; Mice; Paraganglioma; Pheochromocytoma; Zoledronic Acid	2022